Business

Avicanna expanded the medical cannabis brand RHO Phyto to the Caribbean and was the first to export it to the Canadian business journal Barbados.

  • From three SKUs, an advanced medical cannabis prescription collection will be available to the medical community and patients through prescriptions
  • The distribution partnership with Bridenstalks Limited includes the initial focus on Barbados and plans to expand further into the Caribbean region.
  • RHO phytoform and 13th third active countryNSOpening the international market for Avicanna products

Toronto, November 25, 2021 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), Development, Manufacturing, Commercialization of Plant-Derived Cannabinoid-Based Products Caribbeans Rho Phyto Branded Medical Cannabis Products It has expanded to the sea area and announced that it has succeeded in initial export to its distribution partner Bryden Stokes Limited (“Bryden Stokes”). Barbados.

Avicanna has a marketing partnership with Bryden Stokes, an established health and pharmaceutical distributor in the Caribbean, selling the RHO Phyto product line of medical prescriptions starting with three product SKUs. This is the third country where RHO Phyto’s prescription collection is available13NS The international market where Avicanna’s product portfolio has been successfully exported.

The company plans to bring RHO Phyto products to the Caribbean medical community and patients through Bridenstokes’ extensive network and sales infrastructure in Barbados and other regions. In addition to advanced, evidence-based products, Avicanna extends a comprehensive educational platform that includes patient support, marketing and training.

The first deliveries, including oral and sublingual products, were successfully exported from Canada through Avicanna’s strategic partnership with leading pharmaceutical cannabis maker Medipharm Labs (TSX: LABS). Specifically, Barbados will commercialize its products under the Medical Cannabis Industry Act 2019-44, which outlines regulations on the handling of medical cannabis on the island. Avicanna plans to expand its product offerings to the region to include additional SKUs from the Canadian portfolio and medicines from the Colombian prescription collection.

“We are pleased to extend Rho Phyto’s product formulation to Barbados. Partner Bryden Stokes shares a vision with a focus on providing scientifically advanced evidence-based cannabis products to the medical community and patients. We look forward to establishing RHO Phyto as the gold standard for the entire region and aim to build long-term opportunities for the brand, “said CEO Alas Azadian.

Briden Stokes is pleased to begin a partnership with Avicanna to provide pharmaceutical grade medical cannabis to patients in Barbados and the East Caribbean. Specifically, it is a Rho Phyto brand product. Avicanna’s evidence-based approach to prescribing and collaboration with major academic and clinical institutions make Avicanna an ideal partner.

About Bridence Talks

Briden Stokes has three different business units: Food and Consumer, Brewery, Wine, Spirits and Tobacco, Health and Wellness. Their extensive network of international suppliers and a thriving portfolio make it one of Barbados’ major distributors. To support these departments, we have a portfolio of over 330 employees and 450 high quality brands.

About RHO Phyto

Highly standardized formulations include various doses of cannabidiol (“CBD”), tetrahydrocannabinol (“THC”), and THC-free options for a variety of oral, sublingual, transdermal, and topical drugs. A range of cannabinoid-based solutions that are delivered in a delivery format and are inhalation-free to consumers. The unique formulation has been developed and optimized by Avicanna to enhance absorption while providing a consistent experience with a pleasant taste and aroma. RHO Phyto products are delivered in accurate dosages, making it easy for consumers to titrate and administer.

Avicanna’s RHO Phyto vision is to provide consumer, retailer, and medical circles with product education and secure delivery through evidence-based training and education. Avicanna aims to establish RHO Phyto as a recommended brand within the cannabis industry and has launched several preclinical and real-world evidence clinical trials of its products with leading Canadian medical institutions. ..

To the best of our knowledge, we operate in compliance with all applicable laws in the jurisdiction in which we do business.

About Abicanna

Avicanna is a Canadian commercial-stage biopharmacy company founded in the cannabinoid research and development, and evidence-based products for global consumers, as well as the medical and pharmaceutical market segments. In advancing the world’s leading cannabinoids, Avicanna conducts most of her research in Canada at the Johnson & Johnson Innovation Center in the MaRS Discovery District and the R & D headquarters in JLABS @ Toronto. The company actively collaborates with major Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform, including advanced R & D and clinical development, leading to the commercialization of more than 20 products across four major market segments.

  • Medical Cannabis and Wellness Products: These medical and wellness products, sold under the RHO Phyto ™ brand or Magical Preparations, are an advanced line of pharmaceutical grade cannabis products, including different proportions of CBD and THC. The product portfolio includes complete formulations of products including oral, sublingual, topical, and transdermal delivery, enhancing dose control, absorption, and stability studies supported by preclinical data. It has been. Advanced prescription collections are sold with education and training for consumers, patients, and the medical community. Avicanna’s healthcare and wellness product portfolio also forms the basis of our pharmaceutical pipeline with data generated from the contribution of the underlying pharmaceutical product, product sales and participation in real-world evidence research.
  • CBD Skin Cosmetics: These registered clinically tested skin cosmetics sold under the PuraH & W ™ or PuraEarth ™ brand include a portfolio of functional CBD topical products.
  • Pharmaceutical Pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna is an indication-specific, patent-pending drug candidate at various stages of clinical development and commercialization. I have created a pipeline. These cannabinoid-based drug candidates provide solutions for unmet medical needs in the areas of dermatology, chronic pain, and various neuropathy. Avicanna’s first drug (Trunerox) is in the drug registration stage in South America.
  • Cannabis Ingredients, Seeds, and Bulk Formulations: The company’s ingredients business, sold under the Auureus ™ brand, has successfully completed sales to 11 countries. Aureus includes dried cannabis flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, isolated cannabinoids (CBD, THC, cannabigerol (“CBG”) and other rare cannabinoids), and theirs. Offering bulk formulations derived from hemp and cannabis growers in a sustainable and economical way, and an industrial-scale subsidiary based in Colombia. The majority of Aureus products are produced by our majority-owned subsidiary, Santa Marta Golden Hemp SAS (“SMGH”). This subsidiary is Good Agricultural and Collection Practices (“GACP”) certified and USDA (“USDA”) National Organic Program Certification for its hemp cultivars.

Source Avicanna Inc.

Stay connected

For more information on Avicanna, please visit www.avicanna.com, email IvanaMaric to info @ avicanna.com, or follow us on social media @avicannainc.

The company posts updates through a video from the official company YouTube channel https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA.

Precautions regarding information and statements regarding future prospects

This news release contains “forward-looking information” in the sense of applicable securities law. The forward-looking information contained in this press release is “May”, “Yes”, “Done”, “Yes”, “Probably”, “Expect”, “Expect”, “Expect”. It can be identified by using words such as “believe”. , “Intention”, “Plan”, “Predict”, “Project”, “Estimate”, “Forecast” and other similar expressions. Contains a description of SMGH’s ability to maintain a license to grow cannabis, and SMGH’s ability to maintain. SMGH’s ability to supply its certifications, current or newly acquired certifications to other companies, or SMGH’s ability to obtain new certifications or business partnerships. Information about future prospects is not a guarantee of future performance and is in light of management’s experience and trends, perceptions of current and expected developments, and other factors related to the situation, including: Based on many estimates and assumptions. Assumptions about current and future market conditions, current and future regulatory environments. Availability of licenses, approvals and permits. We believe that the expectations and assumptions underlying such forward-looking information are reasonable, but we cannot provide any assurance that they are correct, so the forward-looking information You should not put too much trust in it. Actual results and progress may differ materially from those envisioned in these statements. Forward-looking information is subject to various risks and uncertainties in which actual events and outcomes may differ materially from those predicted in the forward-looking information. Such risks and uncertainties are described in current and future market conditions, including market prices for our common stock, as well as in our annual information form and final short form dated September 3, 2021. Risk factors include, but are not limited to. The prospectus dated 27 November 2020 has been submitted to the Canadian Securities Regulatory Authority and is available under our profile on SEDAR at www.sedar.com. The description of this press release was made as of the date of this release. We disclaim any intention or obligation to update forward-looking information as a result of new information, future events or consequences, etc., except as required by applicable securities law.

Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eacc05e3-aa55-4411-95be-e5ee2854ad7e.


CBJ News Maker

Avicanna expanded the medical cannabis brand RHO Phyto to the Caribbean and was the first to export it to the Canadian business journal Barbados.

Source link Avicanna expanded the medical cannabis brand RHO Phyto to the Caribbean and was the first to export it to the Canadian business journal Barbados.

Related Articles

Back to top button